BEVERLY, Mass.--(BUSINESS WIRE)--ZymeQuest, Inc. today announced that it has entered into an exclusive worldwide agreement to license certain patent applications associated with its proprietary enzyme conversion technology to a publicly traded U.S. life sciences company. The licensee plans to use the enzyme technology for product applications associated with its business, which is outside ZymeQuest’s areas of focus. ZymeQuest retains all rights to the use of its patent applications in the development of products related to transfusion medicine.
